

1F-106-C100

Monoclonal Antibody to Cytokeratin 18 Fluorescein (FITC) conjugated (0.1 mg)

Clone: C-04

Isotype: Mouse IgG1

Specificity: The antibody C-04 reacts with Cytokeratin 18 (45 kDa), a member of intermediate

filaments subfamily represented in epithelial tissues.

Regulatory Status: RUO

Immunogen: Cytoskeleton preparation of epidermal carcinoma cell line A431.

Species Reactivity: Mammalian

Preparation: The purified antibody is conjugated with Fluorescein isothiocyanate (FITC) under

optimum conditions. The reagent is free of unconjugated FITC.

Concentration: 0.1 mg/ml

Storage Buffer: The reagent is provided in stabilizing phosphate buffered saline (PBS) solution

containing 15mM sodium azide.

Storage / Stability: Store in the dark at 2-8°C. Do not freeze. Avoid prolonged exposure to light. Do not

use after expiration date stamped on vial label.

Usage: The reagent is intended for Flow Cytometry analysis.

Expiration: See vial label

Lot Number: See vial label

Background: Cytokeratins are a subfamily of intermediate filaments and characterized by

remarkable biochemical diversity. Cytokeratins are represented in epithelial tissues by at least 20 different polypeptides, molecular weight between 40 kDa and 68 kDa. The individual cytokeratin polypeptides are designated 1 to 20 and divided into the type I (acidic cytokeratins 9-20) and type II (basic to neutral cytokeratins

1-8) families.

Cytokeratins 18 belongs to type I family (acidic cytokeratins).



PRODUCT DATA SHEET

References:

*Taylor-Papadimitriou J, Stampfer M, Bartek J, Lewis A, Boshell M, Lane EB, Leigh IM: Keratin expression in human mammary epithelial cells cultured from normal and malignant tissue: relation to in vivo phenotypes and influence of medium. J Cell Sci. 1989 Nov;94 (Pt 3):403-13.

*Kovarik J. et al., J. Tumor Marker Oncol. 5, 219 (1990).

*Cap J, Cerman J, Nemecek S, Marekova M, Hana V, Frysak Z: The influence of treatment with somatostatin analogues on morphology, proliferative and apoptotic activity in GH-secreting pituitary adenomas. J Clin Neurosci. 2003 Jul;10(4):444-8. *Lauerova L, Kovarik J, Bartek J, Rejthar A, Vojtesek B: Novel monoclonal antibodies defining epitope of human cytokeratin 18 molecule. Hybridoma. 1988 Oct;7(5):495-504.

*Kovarik J, Rejthar A, Lauerova L, Vojtesek B, Bartkova J: Monoclonal antibodies against individual cytokeratins in the detection of metastatic spread. Int J Cancer Suppl. 1988;3:50-5.

*Vojtesek B, Staskova Z, Nenutil R, Lauerova L, Kovarik J, Rejthar A, Bartkova J, Bartek J: Monoclonal antibodies recognizing different epitopes of cytokeratin No.18. Folia Biol (Praha). 1989;35(6):373-82.

*Bartek J, Vojtesek B, Staskova Z, Bartkova J, Kerekes Z, Rejthar A, Kovarik J: A series of 14 new monoclonal antibodies to keratins: characterization and value in diagnostic histopathology. J Pathol. 1991 Jul;164(3):215-24.

Unless indicated otherwise, all products are For Research Use Only and not for diagnostic or therapeutic use. Not for resale or transfer either as a stand-alone product or as a component of another product without written consent of EXBIO. EXBIO will not be held responsible for patent infringement or other violations that may occur with the use of our products. All orders are accepted subject to EXBIO's term and conditions which are available at www.exbio.cz.